To date, there are no approved drugs for the prevention or treatment of any sensorineural hearing loss disorder or tinnitus. AudioCure Pharma is determined to change this.
AudioCure Pharma GmbH is a pharmaceutical company with a focus on hearing impairments. Operational since 2012, AudioCure was founded by Professor Hans Rommelspacher; a clinician and academic who has dedicated his career to the discovery and preclinical development of drug candidates. He is joined by highly skilled scientists and executives as well as a tight-knit network of academic partners, internationally renowned advisors and strategic investors.
Taking a comprehensive approach to hearing loss
AudioCure is based in Berlin, Germany. Our office is located in a peaceful courtyard in the central area of Mitte. As such, we benefit from being within easy reach of the main train station and many other Berlin high-tech companies and universities while also enjoying the hustle and bustle of this vibrant capital city. We have close ties to the Charité University which allows for a close interaction with the experts of this world renowned institution. Our front-runner compound AC102 is currently being evaluated in a Phase II clinical trial for the treatment of idiopathic sudden sensorineural hearing loss. The Phase I study in healthy volunteers has been successfully completed in 2021.